New Antibodies Identified To Treat Blood Clotting Auto-immune Disease

Immune thrombocytopenia, is a rare auto-immune disease where the body's own antibodies kills the blood cells responsible for blood clotting.

Immune thrombocytopenia (ITP) is an autoimmune disease where the immune system sends antibodies to attack and destroy the body's platelets--blood cells responsible for controlling bleeding.

Stopping ITP is important because if platelet //counts in a body are low, simple cuts could bleed for hours and more traumatic injuries could be fatal. The body's inability to control bleeding can also lead to stroke.

Thrombocytopenia / Low Platelet Count - Causes Symptoms Diagnosis Treatment
Thrombocytopenia or low platelet count develops when platelet levels fall below normal range caused by destruction of existing or newly formed platelets. TAR is a rare and inherited disorder.

ITP affects one in 10,000 people in Canada and accounts for 0.18% of all hospital admissions. Most cases are spontaneous and without any clear cause. The severity of ITP and the effectiveness of its treatment vary from patient to patient.

The surface of every platelet is covered with thousands of different proteins and each type of antibody targets a specific protein on the platelet. The first antibody to find a platelet latches on and leads the platelet to an organ where it will be destroyed.

"Every existing treatment for ITP has been dedicated to stopping antibodies from destroying platelets in the spleen, but we've discovered that some antibodies actually destroy platelets in the liver," said Dr. Heyu Ni, a scientist in the Keenan Research Centre for Biomedical Science of St. Michael's Hospital.

IPS Cell Technology Used for Modeling of Congenital Amegakaryocytic Thrombocytopenia
Researchers reveal that they have managed to induce iPS cells generated from a patient with congenital amegakaryocytic thrombocytopenia to differentiate into blood cells.

The discovery was made by looking mice treated with two different types of antibodies most common to ITP. Each of these two antibodies targets a different protein on the surface of platelets--either GPIb or GPIIbIIIa. The researchers found that antibodies targeting GPIb lead to platelets to be destroyed in the liver, whereas those targeting GPIIbIIIa caused platelet destruction in the spleen.

"By detecting the specific antibodies present in someone with ITP, we may be able to detect where and how the immune system will attack," said Dr. Heyu Ni, who is also a scientist with Canadian Blood Services and a professor at the University of Toronto. "And because we now know the liver's immune response destroys platelets covered with GPIb, we may be able to design new therapies to stop this type of platelet destruction."

Study Says Romiplostim More Effective Than Standard Care for Immune Thrombocytopenia
An FDA-approved drug to treat the rare autoimmune disorder immune thromobocytopenia (ITP) is more effective than earlier medical therapies in helping patients avoid surgical treatment

Dr. Ni said that there are drugs, such as Tamiflu, which may be able to inhibit the liver's immune response to the platelets. "Using healthy blood samples and ITP antibodies in a test tube, we showed that Tamiflu may impede platelet destruction for those with antibodies that target GPIb," said Dr. Ni.

Based on an early abstract of this research study, some individuals around the world with ITP have been given Tamiflu to treat the disease. These people were in life-threatening condition and extremely drug-resistant to existing treatments targeting the spleen. Although these instances of experimental treatment have been successful, Dr. Ni said more research is needed to verify the safety and efficacy of this approach.

Platelet Drug Benefits Aplastic Anemia Patients
Eltrombopag raises blood cell levels in people with severe aplastic anemia, say researchers.

Source-Eurekalert